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Abstract
Non-Hodgkin lymphoma (NHL) arising in the context of immunosuppression is an important 
adverse outcome following solid organ transplantation. Diffuse large B-cell lymphoma (DLBCL) 
is the most commonly diagnosed subtype of post-transplant NHL, but few studies of transplant 
recipients have examined subtype-specific risks. Therefore, we examined DLBCL risk in the 
Transplant Cancer Match Study, including registry-based cancer ascertainment among 96,615 
solid organ transplants performed from 2000–2008. We determined standardized incidence ratios 
(SIRs) and 95% confidence intervals (CIs) comparing DLBCL risk in transplant recipients to that 
in the general population, and used multivariable Poisson regression models to assess the impact 
of potential risk factors. We identified 321 incident cases of DLBCL, over 12 times more than 
expected based on general population rates (SIR=12.6, 95% CI=11.2–14.0). SIRs were highest in 
young recipients and those receiving a lung or pancreas/kidney-pancreas transplant, and were 
greatly elevated for extranodal DLBCLs at the site of the transplant compared to other sites. 
DLBCL risk was highest in the first year following transplant, and SIRs for early-onset DLBCL 
risk were elevated in association with EBV negative serostatus and use of polyclonal antibody 
induction therapy. In conclusion, associations between recipient and transplant factors and post-
transplant DLBCL risk suggest a complicated interrelationship among multiple risk factors and 
timing of disease.
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Introduction
Over 28,000 solid organ transplants are performed annually in the United States (1). 
Improved survival of transplant recipients in recent decades is due in large part to the 
effectiveness of current immunosuppressive therapies in preventing organ rejection, but the 
acute and long-term immunosuppression also increases recipients’ risk of a number of 
malignancies (2–7). In particular, post-transplant lymphoproliferative disorder (PTLD) is a 
major cause of morbidity and mortality in transplant recipients (8). Epstein-Barr virus 
(EBV) is prominent in the etiology of PTLD (9), but recipient age, variations in 
pharmacologic immunosuppression, and type of organ transplanted have also been 
associated with PTLD risk (8, 10). In addition, some studies have suggested important 
differences in disease characteristics by time of onset (11–17), EBV involvement (12, 13, 
15, 18, 19) or primary site of disease (20–23).
Most previous research on lymphoma risk in transplant recipients has focused on PTLD or 
non-Hodgkin lymphoma (NHL). However, PTLD comprises a group of clinically and 
molecularly heterogeneous diseases ranging from plasmacytic hyperplasia to malignant 
NHL (24), and NHL includes numerous subtypes that have been shown to have different 
etiologies in the general population (25), as well as varying risks after transplantation (26–
28). Immunosuppression has been associated with strikingly high risks of diffuse large B-
cell lymphoma (DLBCL), a common and clinically aggressive lymphoma (29). A previous 
population-based study found a significantly increased risk of DLBCL after kidney 
transplantation, but did not include other organ transplants or examination of risk factors 
(30).
We therefore examined risk for DLBCL among solid organ transplant recipients. We used 
data from the Transplant Cancer Match Study, which includes systematic registry-based 
ascertainment of cancer in transplant recipients and data on a range of possible risk factors 
(3). We restricted our analysis to transplants performed during 2000–2008 because clinical 
practice regarding transplantation and immunosuppression has changed considerably over 
time, and because of increased availability of data on EBV status in more recent years. We 
included examination of risks by recipient EBV serostatus, timing of DLBCL onset, and 
primary site of disease.
Materials and Methods
Transplant Cancer Match Study
The Transplant Cancer Match Study (www.transplantmatch.cancer.gov) has been described 
previously (3). Briefly, linkage was performed between the Scientific Registry of Transplant 
Recipients (SRTR), which collects data on all solid organ transplants in the United States, 
and 14 population-based U.S. cancer registries. Computer-based linkage was based on 
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subjects’ name, sex, date of birth, and social security number, and was followed by manual 
review of potential matches. Transplant recipients residing in the geographic coverage area 
of the cancer registries were included, and cancer ascertainment was at least 95% complete 
throughout follow-up (3).
For this analysis, we quantified risk of DLBCL in a cohort of 96,615 solid organ transplants 
performed from 2000–2008, representing over 40% of all solid organ transplants in the 
United States during that time. Recipients included in the Transplant Cancer Match Study 
were similar to those outside the linked cancer registries (3). The study was approved by 
human subjects committees at the National Cancer Institute and, as required, participating 
cancer registries (3).
Cancer Ascertainment and Risk Factor Data
Incident cases of DLBCL among transplant recipients were identified from the 14 linked 
population-based cancer registries using International Classification of Diseases for 
Oncology, Third Edition (ICD-O-3) morphology codes 9678–9680 or 9684 (31). Primary 
DLBCL site was classified as nodal or extranodal using ICD-O-3 topography codes, and 
extranodal cases were further classified as arising at the transplanted organ (“transplant-site 
DLBCL”) or at any other extranodal site (“extranodal DLBCL”). Recipients with missing 
codes or determined to have multiple organs involved but with unknown primary site of 
origination (codes C779 and C809) were categorized as having extranodal disease. The 
assignment of transplant-site DLBCL was based solely on organ concordance (e.g., DLBCL 
of any kidney in a kidney recipient), as it was not always possible to determine whether the 
DLBCL arose in the donor or remaining native organs.
Data on risk factors were obtained from the SRTR records, including recipient 
characteristics (sex, age at transplant, race/ethnicity) and transplant characteristics (organ, 
number, calendar year). EBV serostatus of transplant recipients was available for 58% of 
transplants performed after 1999. Immunosuppressive medication use at initial discharge 
was obtained from SRTR as well, and induction therapies were categorized as either 
polyclonal antibodies or IL-2 receptor antagonists (monoclonal antibodies and alemtuzumab 
were used too infrequently to include in the analyses). Drugs typically used in the 
maintenance phase of immunosuppression, such as cyclosporine, tacrolimus, and 
mycophenolate mofetil, were not included in these analyses due to the high likelihood of 
changes in these medications after transplant (32).
Statistical Analyses
Follow-up for cancer risk started at the date of transplantation and continued until the 
earliest of death, failure of a transplanted organ, a subsequent transplant, loss to follow-up, 
or the last date of cancer registry coverage. Recipients were considered at risk separately 
during successive transplant episodes, and were not censored upon first cancer diagnosis 
unless the first cancer was NHL.
We compared risk of developing DLBCL among transplant recipients to that of the general 
population by calculating standardized incidence ratios (SIR = number of cases observed in 
the transplant cohort/number of cases expected in the general population). Expected counts 
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were obtained by applying general population DLBCL rates to the person-time at risk 
among transplant recipients, stratified by sex, age (5-year intervals), race/ethnicity, calendar 
year, and cancer registry (3). Ninety-five percent confidence intervals (95% CI) were 
obtained using an exact method assuming a Poisson distribution for the observed count (33). 
Incidence rates (IRs) were also calculated as observed cases/person-years of follow-up.
We examined the impact of possible risk factors for DLBCL by calculating IRs, SIRs and 
95% CIs among strata of these factors. Primary analyses estimated relative risks (RRs) by 
comparing SIRs among different strata in multivariable Poisson regression models, adjusted 
for sex, race/ethnicity, age at transplant, type of organ transplanted, and calendar year. 
Given the expected importance of recipient EBV serostatus and the potential for residual 
confounding due to missing data, we included comparisons after stratification by recipient 
EBV serostatus. We also stratified by time period after transplant. “Early-onset DLBCL” 
was defined as disease diagnosed within two years of the transplant date, whereas DLBCL 
diagnosed after two years was termed “late-onset”. For analyses stratified by primary 
anatomic site of DLBCL, site-specific SIRs were calculated for transplant-site DLBCL, 
extranodal DLBCL, and nodal DLBCL, with distinct expected values calculated for each 
category. Site-specific analyses of DLBCL were restricted to the major transplanted organ 
types (kidney, pancreas-kidney, liver, heart, and lung).
To assess whether the effects of risk factors differed by time of disease onset or primary 
DLBCL site, we tested for interactions with the relative risks by fitting separate Poisson 
regression models to the different cohorts (e.g., early-onset disease and late-onset disease), 
then combining the cohorts and using the corresponding scores to compute a robust variance 
estimate for all model parameters that accounted for the repeated use of the same individuals 
(34). Differences between association parameters for early- versus late-onset DLBCL or 
transplant site versus other site DLBCL were then assessed using a Wald test. All analyses 
were conducted using SAS statistical software version 9.1.3 (SAS Institute, Inc.), and 
significance of associations was based on α < 0.05.
Results
We examined a cohort of 96,615 transplants performed in the U.S. from 2000–2008 (median 
follow-up time = 2.5 years). As shown in Table 1, 61% of transplant recipients were male, 
8% were age 0–19 years at time of transplant (median age at transplant = 49 years), and the 
most commonly transplanted organs were kidney (59%), liver (22%), and heart (8%).
We identified 321 incident cases of DLBCL, over 12 times more than expected based on 
rates in the general population (SIR=12.6, 95% CI=11.2–14.0; Table 1). DLBCL was the 
most common NHL subtype in transplant recipients, comprising 63% of all NHL cases. IRs 
for DLBCL were high in the youngest transplant recipients, decreased with increasing age at 
transplant until age 40–49, and then rose steadily with increasing age. In contrast, risk 
relative to the age-matched general population was greatly increased in the youngest 
recipients (SIR=1738 for age 0–9 years), and decreased continuously with increasing age at 
transplant, to an SIR of 5.3 in the oldest recipients (age 70+ years). SIRs were modestly 
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higher for females compared to males (P=0.05), and for non-Hispanic whites compared to 
other racial/ethnic groups (P=0.01).
DLBCL risk was strongly associated with type of organ transplant (Poisson regression 
P<0.001) and recipient EBV serostatus (P<0.001), including adjustment for age at transplant 
and other factors (Supplemental Table 1 shows the distribution of organ type by age at 
transplant). The highest elevations in risk were for lung transplants (SIR=41.3), pancreas/
kidney-pancreas transplants (SIR=33.1), and EBV seronegative recipients (SIR=43.6; Table 
1). Overall, DLBCL risk did not differ significantly by transplant number, year of transplant, 
or use of either polyclonal antibodies or IL-2 receptor antagonists as induction 
immunosuppressive therapy.
Risk of developing DLBCL was highest during the first year after transplantation 
(SIR=24.1; Figure 1A). Risks were markedly lower after the first two years and remained 
relatively constant from three to nine years after transplant. Although EBV seronegative 
recipients had greater elevations in risk than seropositive recipients during the first year after 
transplant, both groups experienced the highest risks in this first year (Figure 1B). SIRs 
decreased dramatically after the first year in both groups, but they continued to decline over 
nine years of follow-up for EBV seronegative recipients, whereas EBV seropositive 
recipients showed an increasing trend after three years post-transplantation. Similar patterns 
were observed regardless of the type of organ transplanted (not shown).
When considering recipient EBV serostatus and time period after transplant (Table 2), the 
risk for early-onset DLBCL was significantly higher (P<0.001) in EBV seronegative 
recipients (SIR=78.7) than in EBV seropositive recipients (SIR=11.8). In contrast, the risk 
for late-onset DLBCL was not significantly different between EBV seronegative (SIR=11.4, 
not shown) and seropositive (SIR=6.7) recipients. Few cases of late-onset disease were 
identified in EBV seronegative recipients (N=11), preventing further examination of risk 
factors within this group.
For early-onset DLBCL, the pattern of strikingly high SIRs in the young and declining SIRs 
with increasing age was evident in both EBV seronegative and seropositive recipients (both 
Ptrend<0.001; Table 2). SIRs based on a small number of cases suggested a similar age-
dependent risk pattern for late-onset DLBCL, but only EBV seropositive recipients were 
examined. The highest risks were found following lung transplantation regardless of EBV 
serostatus and time since transplant, with SIRs for lung recipients approximately four-fold 
higher than those for kidney recipients. In contrast, the SIRs for DLBCL after liver 
transplantation were significantly higher than those after kidney transplantation only in 
EBV-seropositive recipients (regardless of time since transplant). In analyses of specific 
immunosuppressive medications, use of polyclonal antibody induction therapy was 
associated with increased risk of early-onset DLBCL in EBV seronegative recipients 
(RR=2.9, 95% CI=1.6–5.0). In contrast, use of IL2 receptor antagonists was associated with 
decreased risk of early-onset DLBCL in EBV seropositive recipients (RR=0.5, 95% CI=0.3–
0.9). Use of specific immunosuppressive medications was not significantly related to risk of 
late-onset DLBCL.
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Although the incidence of DLBCL occurring in the transplanted organ was low, the SIR was 
substantially higher for DLBCL occurring in the transplanted organ (SIR=186) compared 
with other extranodal sites (SIR=13.3) or lymph nodes (SIR=9.7) (Table 3). Patterns of risk 
by EBV serostatus or transplanted organ did not differ by DLBCL site, although no 
DLBCLs were identified in the heart following heart transplantation. DLBCLs in the 
transplanted organ occurred almost exclusively as early-onset disease (97% of 32 cases), 
with only one case identified more than two years after transplant.
Discussion
We present the first large-scale, population-based study of risk factors for DLBCL following 
solid organ transplantation. As the most common NHL subtype occurring among transplant 
recipients and one of the most aggressive forms of PTLD, DLBCL is likely a primary driver 
of many associations observed in previous studies of transplant-related NHL or PTLD. In 
addition to negative EBV serostatus of the recipient being a prominent risk factor for 
DLBCL, we identified that both young age at transplant and transplant of a lung or pancreas 
were associated with increased risks, regardless of EBV serostatus. Recipients were at 
greatest risk during the first year after transplant, and both recipient EBV serostatus and use 
of polyclonal antibodies as induction therapy were associated with risk only in the early-
onset period. Risk relative to the general population was also considerably greater for 
DLBCL occurring in the transplanted organ than for disease at other sites. Furthermore, our 
results suggest that the impact of induction immunosuppression medications may differ 
according to EBV serostatus of the recipient.
We found greatly elevated risk of DLBCL in the first year after transplant, similar to 
previous reports for NHL overall (16, 23). The initial increase in risk we observed soon after 
transplantation was more dramatic than some previous studies of NHL, likely reflecting both 
the subtype-specificity of the outcome in our study and the inclusion of organ transplants 
other than kidneys. The risk of early-onset DLBCL was particularly striking among EBV 
seronegative recipients, supporting the prominent role of uncontrolled primary EBV 
infection in lymphomas occurring immediately following transplant (15, 16, 18, 20). A 
recent study of kidney transplants in Australia reported evidence for two distinct 
mechanisms of lymphomagenesis, with early disease caused largely by primary EBV 
infection during acute immunosuppression, and late disease attributed to aberrant 
proliferation secondary to prolonged immunosuppression (15). Our results generally support 
this model of lymphomagenesis for development of DLBCL. Although we observed that 
risk of DLBCL was also greatest in the first post-transplant year for EBV seropositive 
recipients, the finding may be explained by reactivation of latent EBV infection.
In analyses stratified by EBV serostatus and time since transplantation, we found that risks 
were highest for early-onset DLBCL among pediatric recipients. Increased risk for those 
transplanted at a young age has been established for NHL and PTLD, but the increase is 
typically attributed to the high prevalence of EBV seronegativity in this group. However, we 
found that young age at transplant was associated with increased DLBCL risk among EBV 
seropositive recipients, suggesting the young immune system may also be particularly 
susceptible to immunosuppression-induced EBV reactivation.
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Patterns of DLBCL risk by organ type were similar across strata of EBV serostatus and 
timing of disease onset, with the notable exception of liver transplants. Among EBV 
seronegative recipients, DLBCL risk was lower for liver transplants than for heart or kidney 
transplants, whereas liver transplants had higher relative risk of DLBCL among EBV 
seropositive recipients. Furthermore, among EBV seropositive recipients, only liver 
transplants had similarly increased risks for both early- and late-onset disease. Our results 
suggest EBV seronegativity is a risk factor for DLBCL after liver transplantation, but they 
also support previous findings from studies of NHL suggesting that the role of EBV may 
differ for liver transplants compared to other types of organ transplant (18, 19). The greater 
mass of donor lymphatic tissue delivered with a liver transplant has been hypothesized as a 
possible mechanism explaining the differences in risk by organ (18). We found the highest 
DLBCL risk among persons receiving lung transplants, which may support the importance 
of donor lymphoid mass in addition to intensity of immunosuppression. However, in 
contrast to liver transplants, relative risk in lung transplants remained high regardless of 
EBV serostatus or timing of DLBCL onset. Detailed examinations of lymphoma risk in lung 
transplants have not been reported in previous studies.
Induction therapies for the prevention of acute rejection include polyclonal antibodies, 
which result in severe and prolonged depletion of T-cells, and IL-2 receptor antagonists, 
which inhibit T-cell activation (35). Use of polyclonal antibodies for induction therapy was 
associated with increased risk of early-onset DLBCL only among EBV seronegative 
recipients, suggesting T-cell depletion strongly impairs the immune response to primary 
EBV infection. A previous study found increased risk of early-onset, but not late-onset, 
NHL with use of polyclonal antibodies for induction therapy, but did not isolate the 
association to EBV seronegative recipients (15). The lack of association in EBV seropositive 
recipients may indicate that polyclonal antibody-induced lymphocyte depletion has a less 
profound impact on EBV reactivation, but other patient factors influencing choice of 
immunosuppressive agent may also be important. Our finding that use of IL2 receptor 
antagonists was associated with reduced risk of early-onset DLBCL in EBV seropositive 
recipients may be due to chance, as it is not readily explained and has not been reported in 
previous studies of NHL. Late-onset DLBCL risk is more likely to be influenced by 
maintenance medications and changes in medication use over time, which were not included 
in this analysis.
Although DLBCLs occurring at the site of the transplanted organ were uncommon, risk 
relative to the general population was much higher than for other extranodal sites or lymph 
nodes. This strong increase is consistent with previous literature (21–23, 36), and supports 
the idea that chronic antigenic stimulation by the allograft contributes to lymphomagenesis 
(37), particularly for lung and liver transplants. Notably, almost all DLBCLs in the 
transplanted organ arose in the first two years post-transplant. DLBCL derived from donor 
lymphocytes conveyed with the graft could also play a role, although most cases of PTLD 
are of recipient origin (38). A greater percentage of lymphomas occur extranodally in 
transplant recipients compared to the general population, and prognosis is poor for 
extranodal versus nodal disease (23), but we did not find large differences between risk of 
extranodal DLBCL outside the transplanted organ and risk of nodal DLBCL.
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Strengths of this study include the specific focus on DLBCL and the use of population-based 
registries for ascertainment of both transplants and cancers. The large size of the study 
enabled restriction of analyses to the most recent and clinically relevant time period, as well 
as unique examination of risk factors stratified by both EBV serostatus and timing of disease 
onset. Limitations were primarily based on our use of the transplant and cancer registries for 
exposure and outcome data, which likely resulted in some misclassification.
The proportion of NHL classified as “not otherwise specified (NOS)” was greater in 
Transplant Cancer Match Study cases (20.5%) compared to that expected based on 
population rates (12.4%) (26), and many NHLs classified as NOS are likely DLBCLs. 
Therefore, the DLBCL-specific IRs and SIRs reported may be underestimates. Induction 
medications are administered at the time of transplantation and therefore should be captured. 
However, it is possible that some use of these medications was missed in the reports 
submitted to the SRTR. We investigated the impact of use of polyclonal antibodies and IL2 
receptor antagonists, but had insufficient case numbers to study other types of induction 
medication. Monoclonal antibodies (e.g., OKT3) have been implicated in post-transplant 
lymphoma risk (23, 36, 39), but our study was limited to a recent time period in which use 
of these agents was rare. Our stratified analyses indicated that late-onset DLBCL among 
EBV seropositive recipients was uncommon, preventing detailed examination of risk 
factors. Furthermore, residual confounding due to missing EBV serostatus is possible, 
although we do not expect meaningful differences between recipients with and without EBV 
serostatus data (Supplemental Tables 2 and 3). We did not have data on EBV viral load 
during follow-up or tumor EBV status that could allow better characterization of the role of 
EBV in DLBCL risk.
DLBCL makes up a large proportion of post-transplant NHL and is a primary component of 
associations observed in previous studies of NHL and PTLD. However, full understanding 
of post-transplant lymphoma etiology requires characterization of subtype-specific risks 
(26–28, 30). Our results confirm the prominent role of primary EBV infection in DLBCL 
risk, particularly in the first two years after transplant, and also show age at transplant and 
type of organ transplant to be important risk factors regardless of EBV serostatus. Our 
subtype-specific results provide additional insight into the complicated interrelationship 
among potential risk factors and lymphoid malignancies following transplantation. Future 
work is needed to characterize the role of EBV reactivation, and to further investigate the 
impact of immunosuppressive medication regimens on risk of DLBCL and other NHL 
subtypes.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1A. Risk of diffuse large B-cell lymphoma by time since transplant in solid 
organ transplant recipients in the United States. Standardized incidence ratios (SIRs) and 
associated 95% confidence intervals are shown according to time since transplantation. Each 
point represents the SIR for the previous time interval, with the point centered on the end of 
that time interval (6 months, 1, 2, 3, 4, 5, and 9 years post-transplant). The vertical axis 
shows the standardized incidence ratios on a log-scale.
Figure 1B. Risk of diffuse large B-cell lymphoma by time since transplant in solid 
organ transplant recipients in the United States, stratified by recipient EBV serostatus. 
Standardized incidence ratios (SIRs) and associated 95% confidence intervals (CIs) are 
shown according to time since transplantation and recipient EBV serostatus (open square: 
EBV seronegative; closed triangle: EBV seropositive). Each point represents the SIR for the 
previous time interval, with the point indicating the end of that time interval (6 months, 1, 2, 
3, 4, 5, and 9 years post-transplant). Time intervals are identical for EBV seronegative and 
seropositive recipients; the points are offset to allow distinction of 95% CIs. There were no 
cases among EBV seronegative recipients during the interval between four and five years 
post-transplant, so this interval was combined with the subsequent 6–9 year interval. The 
vertical axis shows the standardized incidence ratios on a log-scale.
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